Genetic testing

Assessment of the cytochrome CYP2C19 activity

Assessment of the P450 2C19 cytochrome activity
Test code: CYP2C19-1

Identification of CYP2C19*2, *3, *6 and *17 haplotypes to assess cytochrome P450 2C19 activity - qualification for treatment with mavacamten (CAMZYOS) and  dosing of drugs such as clopidogrel, and citalopram.

Turnaround time: up to 4 weeks

Price:  660.00 zł
Dodaj do koszyka

We perform genetic testing from:

Ikona opcji  saliva (spitting into a tube is required for sample collection, therefore the kit is not suitable for children under the age of 5)
Ikona opcji  venous blood collected

Assessment of the cytochrome CYP2C19 activity

Mavacamten (Camzyos) is the first cardiac myosin inhibitor acting on the primary pathophysiology of hypertrophic cardiomyopathy (HCM). It was registered in 2023 in all European Union member states for the treatment of hypertrophic cardiomyopathy with left ventricular outflow tract narrowing (oHCM) in adults.
Proper dosing of the drug requires determination of cytochrome P450 2C19 activity (*2 and *3 alleles of the CYP2C19 gene).

Clopidogrel (Plavix) is a drug that prevents the thrombotic complications of vascular atherosclerosis. Clopidogrel is metabolised via cytochrome P450 2C19 (CYP2C19). Patients with a genetically determined low CYP2C19 activity are found to have a lower efficacy of Clopidogrel, leading to a higher incidence of cardiovascular incidents after myocardial infarction compared to patients with normal cytochrome function.
Search list